A great start I feel. Germany is a tough market, demanding and exacting standards. Impressive sales there augur well for Stelfontas market penetration. There might be some resistance possibly from those who profit/ depend on surgical methods. Stelfontas circumvents this traditional method of treatment in many cases. Just my opinion, having read some vet news emphasising TT as an 'option'
- Forums
- ASX - By Stock
- Qbiotics
Qbiotics, page-98
-
- There are more pages in this discussion • 1,177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online